Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Type:
Grant
Filed:
July 23, 2015
Date of Patent:
June 21, 2016
Assignee:
Supernus Pharmaceuticals, Inc.
Inventors:
Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
Abstract: Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.
Type:
Grant
Filed:
February 7, 2013
Date of Patent:
June 7, 2016
Assignee:
Supernus Pharmaceuticals, Inc.
Inventors:
Michael L. Vieira, Austin B. Huang, Padmanabh P. Bhatt
Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Type:
Grant
Filed:
August 26, 2015
Date of Patent:
May 31, 2016
Assignee:
Supernus Pharmaceuticals, Inc.
Inventors:
Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
Abstract: The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and ?-opioid agonistic activity.
Abstract: The present invention is directed to pharmaceutical compositions of psychoactive drugs having a reduced potential for abuse and methods of reducing the potential for abuse of dosage forms of prescription psychoactive drugs.
Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
Type:
Application
Filed:
February 24, 2015
Publication date:
January 28, 2016
Applicant:
Supernus Pharmaceuticals, Inc.
Inventors:
Likan Liang, Hua WANG, Padmanabh P. BHATT, Michael L. VIEIRA
Abstract: Formulations of mazindol having superior stability and methods of administering same are provided. The formulations may be immediate, enhanced, or otherwise delayed release formulations of mazindol.
Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Type:
Application
Filed:
July 23, 2015
Publication date:
December 17, 2015
Applicant:
Supernus Pharmaceuticals, Inc.
Inventors:
Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility-and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Type:
Application
Filed:
August 26, 2015
Publication date:
December 17, 2015
Applicant:
Supernus Pharmaceuticals, Inc.
Inventors:
Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
Abstract: The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
Abstract: Drug formulations having reduced abuse potential which contain one or more of (1) a bittering agent, (2) a bright deterrent/indicator dye and (3) fine insoluble particulate matter. The bittering agent and dye are in a form which does not affect proper administration of the drug, but the bittering agent creates a bitter side effect when the dosage form is crushed or chemically extracted and nasally, orally, buccally or sublingually administered and the dye produces a bright color when crushed and contacted. The fine insoluble particulate matter hinders extraction of the drug from the dosage form and, when crushed, can deter intravenous injection because of the presence of the insoluble particles or hinder injection by blocking an intravenous needle. The bright color of the dye, when extracted, also has a psychologically deterrent effect on intravenous abusers.
Type:
Grant
Filed:
December 8, 2014
Date of Patent:
September 29, 2015
Assignee:
Supernus Pharmaceuticals, Inc.
Inventors:
Rong-Kun Chang, Richard A. Couch, Beth A. Burnside
Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Type:
Grant
Filed:
July 29, 2014
Date of Patent:
September 1, 2015
Assignee:
Supernus Pharmaceuticals, Inc.
Inventors:
Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Type:
Grant
Filed:
July 29, 2014
Date of Patent:
September 1, 2015
Assignee:
Supernus Pharmaceuticals, Inc.
Inventors:
Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
Abstract: Drug formulations having reduced abuse potential which contain one or more of (1) a bittering agent, (2) a bright deterrent/indicator dye and (3) fine insoluble particulate matter. The bittering agent and dye are in a form which does not affect proper administration of the drug, but the bittering agent creates a bitter side effect when the dosage form is crushed or chemically extracted and nasally, orally, buccally or sublingually administered and the dye produces a bright color when crushed and contacted. The fine insoluble particulate matter hinders extraction of the drug from the dosage form and, when crushed, can deter intravenous injection because of the presence of the insoluble particles or hinder injection by blocking an intravenous needle. The bright color of the dye, when extracted, also has a psychologically deterrent effect on intravenous abusers.
Type:
Application
Filed:
December 8, 2014
Publication date:
June 4, 2015
Applicant:
Supernus Pharmaceuticals, Inc.
Inventors:
Rong-Kun CHANG, Richard A. COUCH, Beth A. BURNSIDE
Abstract: Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.
Type:
Application
Filed:
December 19, 2014
Publication date:
May 7, 2015
Applicant:
Supernus Pharmaceuticals Inc.
Inventors:
Likan Liang, Padmanabh P. Bhatt, David Dain, Jean-Philippe Taquet, Aleksandr Pechenov, Alexei Tchesnokov, Reynold Mariaux
Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
Type:
Grant
Filed:
September 29, 2014
Date of Patent:
March 31, 2015
Assignee:
Supernus Pharmaceuticals, Inc.
Inventors:
Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
Abstract: Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone.
Type:
Application
Filed:
April 25, 2014
Publication date:
March 26, 2015
Applicant:
Supernus Pharmaceuticals, Inc.
Inventors:
Rong-Kun Chang, Michael L. Vieira, Likan LIANG, Padmanabh P. BHATT, Austin B. HUANG, Sachin V. PATEL
Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
Type:
Application
Filed:
March 19, 2014
Publication date:
February 26, 2015
Applicant:
Supernus Pharmaceuticals, Inc.
Inventors:
Rong-Kun Chang, Arash Raoufinia, Niraj Shah
Abstract: The present invention is directed towards novel methods of synthesis of molindone, synthesis of the intermediates of molindone, and high-purity compositions of molindone. In particular, the invention relates to the methods of synthesis of molindone through the Mannich reaction.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
February 17, 2015
Assignee:
Supernus Pharmaceuticals Inc.
Inventors:
Martin Hanbauer, Zarghun Nazir, Peter Hildebrand, Attilia Figini, Likan Liang, Tiziano Fumagalli